Resource Logo
Gay Men's Health Crisis

DRUG WATCH: FDA Committee to Consider Vestar's NDA in June




 

GMHC Treatment Issues 1993 May 1; 7(5): 9

The FDA's Oncologic Drugs Advisory Committee will review Vestar's New Drug Application (NDA) for liposomal daunorubicin (DaunoXome) as a treatment for HIV-related Kaposi's sarcoma on June 17, 1993. DaunoXome is the result of a new pharmaceutical manufacturing technique which coats drugs in fatty cells (lipids). Vestar scientists believe the fatty coat increases the ability of the drug to reach its target cells, and reduces drug toxicities. DaunoXome is available via an expanded access program to KS patients in New York, San Francisco and Los Angeles. Call 800/247-3303 for enrollment information. Some analysts predict DaunoXome will be approved by the first quarter of 1994.

Copyright (c) 1993 - GMHC Treatment Issues. Noncommercial reproduction encouraged. Distributed by AEGIS, your online gateway to a world of people, knowledge, and resources. Direct Dial: v.34+: 714.248.2836; v.120/ISDN: 714.248.0433 Internet: telnet:aegis.com www: www.aegis.com



 


Copyright © 1993 -Gay Men's Health Crisis, Publisher. All rights reserved to Gay Men's Health Crisis (GMHC) Treatment Issues. Reproduced with permission. Treatment Issues is published twelve times yearly by GMHC, INC. Noncommercial reproduction is encouraged. Subscription lists are kept confidential. GMHC Treatment Issues, The Tisch Building, 119 West 24th Street, New York, NY 10011 Email GMHC. Visit GMHC

Information in this article was accurate in May 1, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.